
Prothena Corporation plc PRTA
$ 8.56
-2.62%
Prothena Corporation plc DSO Ratio | PRTA
Annual DSO Ratio Prothena Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6.97 | 10.3 | - | - | 14.5 | 30.5 | 0.764 | 3.18 | 61.6 | 116 | 12.6 | 31.3 | 30.6 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 116 | 0.764 | 28.9 |
Quarterly DSO Ratio Prothena Corporation plc
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 4.71 K | - | 3.06 | 5.95 | - | - | - | - | - | - | 0.03 | - | 4.56 | 3.8 | 8.72 | 7.02 | 26.9 | 24.2 | 30.3 | 37.2 | 17.2 | 0.47 | 1.43 | 3.27 | 50.6 | 95.6 | 100 | 0.82 | 73.6 | 95 | 56.8 | 48.8 | 118 | 151 | 108 | 167 | 172 | 78.4 | 106 | 10.4 | 2.45 | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.71 K | 0.03 | 191 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kadmon Holdings, Inc.
KDMN
|
30.6 | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
429 | - | - | $ 256 M | ||
|
XBiotech
XBIT
|
40.8 | $ 1.97 | 3.2 % | $ 60.1 M | ||
|
Neos Therapeutics, Inc.
NEOS
|
150 | - | -2.54 % | $ 57.2 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
54.2 | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
0.0395 | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
365 | $ 1.76 | -2.09 % | $ 2.99 M | ||
|
Translate Bio, Inc.
TBIO
|
69.9 | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
2.34 K | - | - | $ 1.94 B | ||
|
Acceleron Pharma Inc.
XLRN
|
42.2 | - | - | $ 10.9 B | ||
|
Zealand Pharma A/S
ZEAL
|
75.3 | - | 0.52 % | $ 821 M | ||
|
Zogenix, Inc.
ZGNX
|
102 | - | -4.97 % | $ 664 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
4.66 K | - | -7.58 % | $ 264 M | ||
|
Xenon Pharmaceuticals
XENE
|
35.7 | $ 41.4 | 2.35 % | $ 3.28 B | ||
|
Leap Therapeutics
LPTX
|
17.8 | - | 368.57 % | $ 41.9 M | ||
|
Zymeworks
ZYME
|
211 | $ 31.45 | 2.08 % | $ 1.62 B | ||
|
ADMA Biologics
ADMA
|
74.6 | $ 12.67 | -0.98 % | $ 3.02 B | ||
|
Daré Bioscience
DARE
|
877 | $ 0.69 | 1.75 % | $ 7.71 M | ||
|
Fate Therapeutics
FATE
|
122 | $ 1.78 | -8.51 % | $ 211 M | ||
|
Halozyme Therapeutics
HALO
|
93.4 | $ 103.0 | 0.08 % | $ 12.3 B | ||
|
Hutchison China MediTech Limited
HCM
|
93.9 | $ 15.34 | 0.1 % | $ 13.2 B | ||
|
Aptorum Group Limited
APM
|
94 | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
138 | $ 0.78 | -1.89 % | $ 81.2 M | ||
|
Karyopharm Therapeutics
KPTI
|
71.1 | $ 0.02 | -54.5 % | $ 219 | ||
|
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
59.5 | - | - | $ 3.85 B | ||
|
UroGen Pharma Ltd.
URGN
|
88.7 | $ 25.32 | -3.78 % | $ 1.22 B | ||
|
Catalyst Biosciences
CBIO
|
79.3 | $ 13.91 | 1.9 % | $ 1.24 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
ADiTx Therapeutics
ADTX
|
6.94 K | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Apellis Pharmaceuticals
APLS
|
115 | - | - | $ 5.18 B |